Cantor Fitzgerald Estimates Sanara MedTech FY2025 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Investment analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Sanara MedTech in a research note issued on Thursday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($2.92) per share for the year, down from their prior forecast of ($0.88). The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech’s FY2026 earnings at $1.72 EPS.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.33. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. The company had revenue of $26.33 million for the quarter, compared to the consensus estimate of $26.63 million.

A number of other analysts also recently commented on the company. HC Wainwright reduced their price objective on Sanara MedTech from $54.00 to $36.00 and set a “buy” rating for the company in a research report on Friday. Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sanara MedTech has an average rating of “Hold” and a consensus price target of $41.00.

Sanara MedTech Stock Down 2.2%

SMTI stock opened at $21.07 on Monday. Sanara MedTech has a twelve month low of $19.10 and a twelve month high of $38.75. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34. The company has a market cap of $187.52 million, a PE ratio of -4.99 and a beta of 1.21. The business’s 50-day simple moving average is $30.21 and its 200 day simple moving average is $29.79.

Institutional Trading of Sanara MedTech

Large investors have recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in shares of Sanara MedTech during the 1st quarter worth about $326,000. Stephens Inc. AR boosted its position in Sanara MedTech by 18.0% in the second quarter. Stephens Inc. AR now owns 12,794 shares of the company’s stock valued at $363,000 after buying an additional 1,952 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Sanara MedTech by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 13,880 shares of the company’s stock worth $428,000 after buying an additional 826 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Sanara MedTech during the first quarter worth approximately $82,000. Finally, Squarepoint Ops LLC raised its stake in shares of Sanara MedTech by 343.4% in the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after acquiring an additional 24,305 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.